1. Home
  2. BSL vs BWAY Comparison

BSL vs BWAY Comparison

Compare BSL & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackstone

BSL

Blackstone

HOLD

Current Price

$13.49

Market Cap

176.1M

Sector

Finance

ML Signal

HOLD

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

HOLD

Current Price

$19.20

Market Cap

337.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BSL
BWAY
Founded
2010
2003
Country
United States
Israel
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
176.1M
337.9M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
BSL
BWAY
Price
$13.49
$19.20
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$23.50
AVG Volume (30 Days)
71.9K
67.9K
Earning Date
01-01-0001
11-11-2025
Dividend Yield
9.55%
N/A
EPS Growth
N/A
213.09
EPS
N/A
0.13
Revenue
N/A
$49,094,000.00
Revenue This Year
N/A
$330.76
Revenue Next Year
N/A
$22.24
P/E Ratio
N/A
$59.95
Revenue Growth
N/A
27.08
52 Week Low
$12.19
$7.84
52 Week High
$14.56
$19.80

Technical Indicators

Market Signals
Indicator
BSL
BWAY
Relative Strength Index (RSI) 35.83 62.54
Support Level $13.50 $18.31
Resistance Level $13.59 $19.80
Average True Range (ATR) 0.07 0.87
MACD -0.00 0.14
Stochastic Oscillator 15.38 79.63

Price Performance

Historical Comparison
BSL
BWAY

About BSL Blackstone

Blackstone Senior Floating Rate Term Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. It also invests in second-lien loans and high yield bonds and employs financial leverage which may increase the risk to the Fund.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: